Skip to Main Content

Paper Details

Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma.
Oncologist
8
2021
COVID-19, EMD, MM, PD-L1, Patients, RRMM, Relapsed Refractory Multiple Myeloma, T-cell, anti-PD-L1, multiple myeloma, patients, relapsed/refractory multiple myeloma
Author NameAffiliation
Baris TurkbeyCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Peter L ChoykeCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Kevin CamphausenCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Kevin CamphausenCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Maryalice Stetler-StevensonCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Maryalice Stetler-StevensonCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Seth M SteinbergCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Seth M SteinbergCenter for Cancer Research, National Cancer Institute, National Institutes of Health
  • 1 - 8

Datasets

Release 1.2